Eli Lilly shares keep Buy rating on successful Phase III trial results - Investing.com
TD Cowen maintains Buy rating and $1,050.00 price target for Eli Lilly, following successful Phase III trial results for once-weekly insulin efsitora. Analysts predict potential market impact, with efsitora seen as a competitor to Novo Nordisk's icodec. Eli Lilly's financial model has been revised, reflecting heightened expectations. Recent collaborations and acquisitions, including a deal with EVA Pharma and the acquisition of Morphic Holding, add to the company's growth prospects. Eli Lilly's market capitalization stands at $831.03 billion, with impressive revenue growth and consistent dividend payments.
Reference News
TD Cowen maintains Buy rating and $1,050.00 price target for Eli Lilly, following successful Phase III trial results for once-weekly insulin efsitora. Analysts predict potential market impact, with efsitora seen as a competitor to Novo Nordisk's icodec. Eli Lilly's financial model has been revised, reflecting heightened expectations. Recent collaborations and acquisitions, including a deal with EVA Pharma and the acquisition of Morphic Holding, add to the company's growth prospects. Eli Lilly's market capitalization stands at $831.03 billion, with impressive revenue growth and consistent dividend payments.